L1CAM and endometrial carcinoma: L1CAM is included as a risk variable in the ongoing PORTEC-4a trial to evaluate vaginal recurrence after adjuvant treatment or observation based on molecular-integrated risk profile in women with early-stage endometrial carcinoma [15].